GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy Participants
- First Posted Date
- 2011-01-17
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01277718
A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion
- First Posted Date
- 2011-01-14
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 202
- Registration Number
- NCT01277302
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
Phase 3
Completed
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- Drug: PlaceboDrug: H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist
- First Posted Date
- 2010-12-22
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 336
- Registration Number
- NCT01264939
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Phase 2
Completed
- Conditions
- Atherosclerosis
- Interventions
- Drug: MLDL1278ADrug: placeboDrug: statin, stable dose
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 147
- Registration Number
- NCT01258907
Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01254526
An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: GDC-0973 IV InfusionDrug: GDC-0973 Oral Capsules
- First Posted Date
- 2010-11-29
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT01249118
A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants
- First Posted Date
- 2010-11-29
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01249131
A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01243892
A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01240226
- Locations
- 🇺🇸
Investigational Site, Austin, Texas, United States
A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy
- First Posted Date
- 2010-10-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT01229215
© Copyright 2025. All Rights Reserved by MedPath